References
- Decady Y, Greenberg L. Ninety years of change in life expectancy, H.S. Division, Editor. Statistics Canada. 2014;1–10. https://www150.statcan.gc.ca/n1/en/pub/82-624-x/2014001/article/14009-eng.pdf?st=2oJBS-HR
- Lichtenberg FR. The impact of biomedical innovation on longevity and health. Nordic J Health Eco. 2015;5:45–57.
- Kontis V, Bennett JE, Mathers CD, et al. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389:1323–1335.
- ISPOR Council. ISPOR 2018 Top 10 HEOR Trends. 2018 [cited 2018 Sept 18]; Available from: https://www.ispor.org/docs/default-source/publications/top10trends.pdf?sfvrsn=e6052ae7_2.
- Government of Canada. Canada’s health care system. 2016 [cited 2018 Sept 18]; Available from: https://www.canada.ca/en/health-canada/services/canada-health-care-system.html.
- Canadian Life and Health Insurance Association, Canadian life and health insurance facts. Canadian Life and Health Insurance Association (CLHIA); Canada (Toronto, Montreal, Ottawa); 2017. https://www.clhia.ca/web/clhia_lp4w_lnd_webstation.nsf/resources/Factbook_2/$file/2018+FB+EN.pdf
- Picard A. National pharmacare is possible – but it won’t come easy. The Globe and Mail. The Globe and Mail Inc: Canada: Toronto; 2018.
- Fréchette J-D. Federal cost of a national pharmacare program. Ottawa; Office of the Parliamentary Budget Officer; 2017. http://www.pbo-dpb.gc.ca/web/default/files/Documents/Reports/2017/Pharmacare/Pharmacare_EN_2017_11_07.pdf
- Sutherland G, Dinh T. Understanding the gap: A Pan-Canadian analysis of prescription drug insurance coverage. The Conference Board of Canada; Canada; 2017.
- The International Network of Agencies for Health Technology Assessment. The International Network of Agencies for Health Technology Assessment. 2019 [cited 2019 Jan 14]; Available from: http://www.inahta.org/
- Battista RN, Côté B, Hodge MJ, et al. Health technology assessment in Canada. Int J Technol Assess Health Care. 2009;25:53–60.
- Institut National d'Excellence en Santé et Services Sociaux. Evaluation Process and Criteria. 2018 [cited 2018 Oct 04]; Available from: https://www.inesss.qc.ca/en/activities/drug-products/evaluation-process-and-criteria.html.
- Government of Canada. Federal Public Drug Benefit Programs. 2018 [cited 2018 Sept 18]; Available from: https://www.canada.ca/en/health-canada/services/health-care-system/pharmaceuticals/access-insurance-coverage-prescription-medicines/federal-public-drug-benefit-programs.html.
- Glennie J. Assessing Medication Value – One Size Does Not Fit All! 2016 [cited 2018 Sep 18]; Available from: http://bppgcreative.ca/pdfs/r/HTA-private-payer-article-submission-to-Benefits-Canada.pdf.
- Sáaid HB, Stewart D, England I, et al. The Impact of Health Technology Assessment on Decision-Making Processes in Public Versus Not-for-Profit Private Hospitals. American Medical Journal. 2011;2:72–78.
- Sullivan SD, Watkins J, Sweet B, et al. Health Technology Assessment in Health-Care Decisions in the United States. 2009; 12:S39–S44.
- Pericleous L, Rogoza R, Goeree R. Use of health technology assessment for drugs in the private payer environment in canada: a literature review. Canadian Association of Population Therapeutics. Toronto, Ontario: Amgen Canada Inc; 2016.
- Santos CMdC, Pimenta CAdM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino-Am Enfermagem. 2007;15:508–511.
- Fernandez AM, Schrogie JJ, Wilson WW, et al. Technology assessment in healthcare: a review and description of a “best practice” technology assessment process. Best Practices and Benchmarking in Healthcare. 1997;2:240–253.
- Perry S, Thamer M. Health technology assessment: decentralized and fragmented in the US compared to other countries. Health Policy. 1997;40:177–198.
- Davis JB. Cost containment mechanisms in Canada. Croat Med J. 1999;2:287–293.
- Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;36:iii–iv, ix–xi, 1–158.
- Drummond MF, Schwartz JS, Jönsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008;24:244–258. discussion 362-8.
- Bresnahan BW, Neumann PJ, Carlson R, et al. Findings related to assessing value for private us health plans. Am J Pharm Benefits. 2010;2:219–228.
- Bryan S, Sofaer S, Siegelberg T, et al. Has the time come for cost-effectiveness analysis in US health care? Health Econ Policy Law. 2009;4:425–443.
- Goeree R, Levin L, Chandra K, et al. Health technology assessment and primary data collection for reducing uncertainty in decision making. J Am Coll Radiol. 2009;6:332–342.
- Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2009;2:55–58.
- Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics. 2010;28:153–162.
- Marra CA, Bansback N, Anis AH, et al. Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clin Rheumatol. 2011;30(Suppl 1):S9–S18.
- Trosman JR, Van Bebber SL, Philiips KA. Health technology assessment and private payers’ coverage of personalized medicine. Am J Manag Care. 2011;17:SP53–SP60.
- Kratzer J, McGrail K, Strumpf E, et al. Cost-control mechanisms in canadian private drug plans. Healthc Policy. 2013;9:35–43.
- Caro JJ, Möller J. Decision-analytic models: current methodological challenges. Pharmacoeconomics. 2014;32:943–950.
- Klein I, Kolodziej M. Private payers and cancer care: land of opportunity. J Oncol Pract. 2014;10:15–19.
- Moloney R, Mohr P, Hawe E, et al. Payer perspectives on future acceptability of comparative effectiveness and relative effectiveness research. Int J Technol Assess Health Care. 2015;31:90–98.
- Trosman JR, Weldon CB, Douglas MP, et al. Decision making on medical innovations in a changing health care environment: insights from accountable care organizations and payers on personalized medicine and other technologies. Value Health. 2017;20:40–46.
- Garrison LP, Pauly MV, Willke RJ, Jr, et al. An overview of value, perspective, and decision context-A health economics approach: An ISPOR special task force report [2]. Value Health. 2018;21:124–130.
- Garel E. Rewriting the prescription: creative ways to control drug costs. 2011 [cited 2018 Sep 19]; Available from: https://www.benefitscanada.com/benefits/health-benefits/rewriting-the-prescription-creative-ways-to-control-drug-costs-14201.
- Scott-Clarke A. Moving toward a healthier drug plan. 2013 [cited 2018 Sep 19]; Available from: https://www.benefitscanada.com/uncategorized/moving-toward-a-healthier-drug-plan-36176.
- Bonnett C. Making U.S. benefits plan design work in Canada. 2011 [cited 2018 Sep 19]; Available from: https://www.benefitscanada.com/benefits/health-wellness/making-u-s-benefits-plan-design-work-in-canada-18252.
- Bauer G. Think tank evaluates current methods for drug coverage. 2011 [cited 2018 Sep 19]; Available from: https://www.benefitscanada.com/news/think-tank-evaluates-current-methods-for-drug-coverage-17965.
- Advocacy CC. Equality of access for Canadians to new medication. 2009 [cited 2016 Mar 1]; Available from: Centre for ADD/ADHD, http://caddac.ca/cms/CADDAC_pdf/Longacting_medications_policy_paper_March_1_Final.pdf.
- Canadian Agency for Drugs and Technologies in Health. Common drug review-CEDAC final recommendation: Paliperidone palmitate (Invega Sustenna- Janssen Inc.). 2011 [cited 2016 Mar 1]; Available from: https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Invega-Sustenna_April-29-11.pdf.